Friday, July 31, 2026

17.6 Million EVs Sold Last Year With More Than 10 Million Units Sold in China

Global EV sales surged to 17.63 million in 2023, led by BYD in China, while Tesla faced declining sales amid market shifts.

Diplomacy and Unification Ministries Again at Odds Over ‘North Korea Policy Consultation’… Unexpected Internal ROK Conflict

South Korea's Unification Ministry and Foreign Ministry clash over North Korea policy consultations, highlighting internal government disagreements.

Apple vs Epic Games: Will the Supreme Court End the In-App Payment Battle in 2024?

Apple appeals to the Supreme Court over in-app payment fees following a contempt ruling, while Google reduces its app payment fees.

Tag: biosimilars

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

How Celltrion Plans to Cut Biologics Development Costs by 25% Amid FDA Regulation Changes

Celltrion is optimistic about enhanced competitiveness due to eased biosimilar regulations by the FDA, expecting significant cost reductions.

Samsung Biologics: How a 56 Billion USD CDMO Leader is Shaping the Future of Biopharmaceuticals

Samsung Biologics is evolving as a leading CDMO, targeting a production capacity of 1.32M liters by 2030 after its spin-off from Bioepis.

CT-P55: How Celltrion’s New Biosimilar Approval Will Transform Clinical Trials in Europe

Celltrion receives EMA approval to reduce patient enrollment for CT-P55 trial, aiming to cut costs and duration of clinical development.

Celltrion Gets Global IB Upgrades: Morgan Stanley Raises Target to $206.25 as New Biosimilars Lift Margins

Celltrion is expanding through biosimilars and new drug development, attracting global investor interest and raising target stock prices.

Celltrion’s Zymfentra: How This Breakthrough Drug is Driving Record Sales

Celltrion expects record sales driven by Zymfentra's success, expanding into new biosimilars and CDMO business for future growth.

How Celltrion Plans to Expand Its Biosimilar Portfolio to 41 Products by 2038

Celltrion unveils its growth strategy at the JP Morgan Healthcare Conference, aiming to expand biosimilars and develop new drug pipelines.

K-Bio Targets the U.S. Market: Celltrion and Samsung Bioepis Close in on Originator Drugs

Celltrion and Samsung Bioepis are expanding in the U.S. market, showing strong growth in biosimilars like Zymfentra and Hadlima.

Celltrion’s ‘Psoriasis’ Biosimilar Poised to Challenge Big Pharma with Phase 1 Data

The EADV conference in Paris showcased Celltrion's biosimilar CT-P55, confirming its equivalence to Cosentyx in safety and pharmacokinetics.

Bio-Revolution: Celltrion’s $700M Biosimilar Is Reshaping the Global Drug Market

Celltrion's breakthrough in antibody biosimilars is transforming healthcare, enhancing access and innovation in treatment options.

Sales and Trust: How Celltrion is Revolutionizing the European Market Directly Connected

Celltrion leverages direct sales in Europe to enhance trust and supply stability while introducing biosimilars like Omlyclo for asthma treatment.

Celltrion’s Biosimilar Success in Europe Paves the Way for a US Market Takeover

Celltrion's booth at EADV 2025 highlighted biosimilar innovations, showcasing promising clinical trial results and expanding treatment access.

Biosimilars No Longer Second-Best: Highlighting Cost Savings and Improved Patient Access

Biosimilars are becoming standard care, with growing confidence in their safety and efficacy, driven by cost savings and improved accessibility.

Saving Poverty vs Free Trade Society? How Celltrion’s Biosimilar Could Reshape the U.S. Healthcare Market

Professor Metz highlights biosimilars' potential to expand patient access to treatments, emphasizing Omliclo's impact at EADV conference.

Sandoz: Millions of Patients Denied Access to Affordable Enbrel Alternative

Sandoz has filed an antitrust lawsuit against Amgen to challenge patent practices blocking its biosimilar, Erelzi, from market entry.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.